Provided by Tiger Trade Technology Pte. Ltd.

Candel Therapeutics, Inc.

5.83
+0.540010.21%
Post-market: 5.950.1200+2.06%18:54 EST
Volume:734.22K
Turnover:4.24M
Market Cap:320.06M
PE:-10.41
High:5.95
Open:5.46
Low:5.38
Close:5.29
52wk High:13.68
52wk Low:4.25
Shares:54.90M
Float Shares:45.48M
Volume Ratio:1.35
T/O Rate:1.61%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5600
EPS(LYR):-1.7420
ROE:-70.17%
ROA:-43.25%
PB:3.99
PE(LYR):-3.35

Loading ...

Candel Therapeutics Advances Gene-Based Prostate Cancer Trial With New Biomarker Update

TIPRANKS
·
Feb 06

BRIEF-Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule

Reuters
·
Feb 03

Candel Therapeutics Grants New Employee Stock Options Under 2025 Inducement Plan

Reuters
·
Feb 03

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Feb 03

Breakeven On The Horizon For Candel Therapeutics, Inc. (NASDAQ:CADL)

Simply Wall St.
·
Jan 17

Candel Therapeutics Showcases Positive Clinical Trial Data for CAN-2409 in Cancer Immunotherapy

Reuters
·
Jan 12

Candel Therapeutics Showcases Advances in Immune-Based Cancer Therapies in New Corporate Presentation

Reuters
·
Dec 11, 2025

Candel Therapeutics Price Target Maintained With a $15.00/Share by Stephens & Co.

Dow Jones
·
Dec 08, 2025

Candel Therapeutics Q3 Net Income USD -11.269 Million

Reuters
·
Nov 20, 2025

Candel Therapeutics Hosts Virtual R&D Event Showcasing Immunotherapy Pipeline

Reuters
·
Nov 18, 2025

Candel Therapeutics Is Maintained at Buy by Citigroup

Dow Jones
·
Nov 15, 2025

Canaccord Genuity Reaffirms Their Buy Rating on Candel Therapeutics (CADL)

TIPRANKS
·
Nov 14, 2025

Bank of America Securities Sticks to Their Hold Rating for Candel Therapeutics (CADL)

TIPRANKS
·
Nov 14, 2025

Candel Therapeutics Advances Cancer Therapies with Strong Q3

TIPRANKS
·
Nov 14, 2025

Candel Therapeutics Showcases Progress of CAN-2409 and Pipeline Advancements in Cancer Immunotherapy

Reuters
·
Nov 13, 2025

Candel Therapeutics Q3 net loss widens to $11.3 mln

Reuters
·
Nov 13, 2025

BRIEF-Candel Therapeutics Q3 Net Income USD -11.269 Million

Reuters
·
Nov 13, 2025

Candel Therapeutics Q3 Basic EPS USD -0.21

THOMSON REUTERS
·
Nov 13, 2025

Candel Therapeutics Q3 Income From Operations USD -13.207 Million VS. Ibes Estimate USD -11.8 Million

THOMSON REUTERS
·
Nov 13, 2025

Candel Therapeutics Inc: Expect Phase 2 Nsclc Long-Term Survivor Data in Q1 2026 and Phase 3 Initiation in Q2 2026

THOMSON REUTERS
·
Nov 13, 2025